Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of New vs. Conventional WAL 801 CL Dry Syrup
NCT02260050Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2004
- Primary completion
- Jul 2004
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of epinastine in allergic rhinitis (AR), urticaria and asthma (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from 0 to last measurable concentration up to 34 hours and Maximum measured concentration up to 34 hours. Started Jun 2004; status: completed.
02
Drugs
epinastine
03
Conditions
allergic rhinitis (AR)urticariaasthma
Beyond the preview
Go deeper on NCT02260050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02260050.